Stryker's Surpass buy feeds growing neurovasc unit; pares down 2012 and 2013 earnings guidance
This article was originally published in Clinica
Executive Summary
Stryker has bolstered its neurovascular offering by agreeing to acquire Israeli firm Surpass Medical in a deal worth up to $135 million. Privately-held Surpass has developed a device called NeuroEndoGraft, a self-expanding cobalt chromium mesh designed to treat brain aneurysms by redirecting blood flow away from the affected area, allowing a stable clot to be formed in the aneurysm pouch. The device is implanted via a minimally-invasive catheter-based procedure.